Newly developed retatrutide, a twin -action drug targeting both GLP-1 and GIP receptors, is generating considerable buzz within the weight loss community. Initial clinical trials have revealed significant decreases in body mass and improvements in health markers for people with obesity . Experts believe this novel approach has the potential to … Read More